<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156568">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02114892</url>
  </required_header>
  <id_info>
    <org_study_id>RESV-MS</org_study_id>
    <nct_id>NCT02114892</nct_id>
  </id_info>
  <brief_title>Effect of Resveratrol Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion</brief_title>
  <official_title>Effect of Resveratrol Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <authority>Mexico: Local Committee of University of Guadalajara</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Metabolic Syndrome is a high prevalence disease worldwide. About a quarter of the adult
      population suffers the disease.

      Resveratrol is a substance found in many plants, including grapes, nuts and wine, but it's
      also found in Polygonum cuspidatum. There is evidence that resveratrol consumption has
      beneficial effects on glucose and lipids metabolism, blood pressure and body weight.

      The aim of this study was to evaluate the effect of resveratrol on metabolic syndrome,
      insulin sensitivity and insulin secretion.

      The investigators hypothesis was that the administration of resveratrol modifies the
      metabolic syndrome, insulin sensitivity and insulin secretion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, placebo-controlled clinical trial was carried out in 24 patients
      with a diagnosis of metabolic syndrome in accordance with the International Diabetes
      Federation (IDF). Waist circumference, glucose, insulin levels, lipid profile, creatinine
      and acid uric were evaluated after a 75 g of dextrose load.

      12 received resveratrol, 500 mg, three times per day (1500 mg) before meals during 3 months.

      The remaining 12 patients received placebo with the same prescription.

      Area Under the Curve of glucose and insulin was calculated as well as total insulin
      secretion (insulinogenic index), first-phase of insulin secretion (Stumvoll index) and
      insulin sensitivity (Matsuda index).

      This protocol was approved by a local ethics committee and written informed consent was
      obtained from all volunteers.

      Results are presented as mean and standard deviation. Intra and inter group differences were
      tested using the Wilcoxon signed-rank and Mann-Whitney U-test respectively; pâ‰¤0.05 was
      considered significant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline of waist circumference at week 12.</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The waist circumference is going to be evaluated at baseline and week 12 with a flexible tape with standardized techniques. Differences will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of triglycerides levels at week 12</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The triglycerides levels are going to be evaluated at baseline and week 12 with enzymatic-colorimetric techniques. Differences will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of high density lipoprotein (c-HDL) levels at week 12.</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The c-HDL levels are going to be evaluated at baseline and week 12 with enzymatic/colorimetric techniques. Differences will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of fasting glucose levels at week 12.</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The fasting glucose levels are going to be evaluated at baseline and week 12 with enzymatic/colorimetric techniques. Differences will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of blood pressure at week 12.</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The blood pressure is going to be evaluated at baseline and week 12 with a digital sphygmomanometer. Differences will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of first phase of insulin secretion at week 12.</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The first phase of insulin secretion is going to be calculated at baseline and week 12 with Stumvoll index. Differences will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of total insulin secretion at week 12.</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The total insulin secretion is going to be calculated at baseline and week 12 with insulinogenic index. Differences will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of total insulin sensitivity at week 12.</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The insulin sensitivity is going to be calculated at baseline and week 12 with Matsuda index. Differences will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of weight at week 12.</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The weight it's going to be measured at baseline, week 4, week 8 and week 12 with a bioimpedance balance. Differences will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of Body Mass Index at week 12</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Body Mass index it's going to be calculated at baseline and at week 12 with the Quetelet index. Differences will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of total cholesterol at week 12</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The total cholesterol will be estimated by standardized techniques at baseline and week 12. Differences will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of low density lipoproteins (c-LDL) at week 12</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The c-LDL levels are going to be measured at baseline and at week 12 with standardized techniques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of hepatic transaminases at week 12.</measure>
    <time_frame>Baseline. Week 12.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The hepatic transaminases levels are going to be measured at baseline and at week 12 with standardized techniques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of creatinine at week 12.</measure>
    <time_frame>Baseline. Week 12.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The creatinine levels are going to be measured at baseline and at week 12 with standardized techniques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of uric acid at week 12.</measure>
    <time_frame>Baseline. Week 12.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The uric acid levels are going to be measured at baseline and at week 12 with standardized techniques.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Metabolic Syndrome X</condition>
  <arm_group>
    <arm_group_label>Resveratrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Resveratrol capsules, 500 mg, three times per day before meals during 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Calcined magnesia capsules, 500 mg, three times per day before meals during 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Resveratrol</intervention_name>
    <description>Resveratrol capsules of 500 mg three times per day before meals with a total dosis of 1500 mg per day.</description>
    <arm_group_label>Resveratrol</arm_group_label>
    <other_name>Trans resveratrol</other_name>
    <other_name>3, 5, 4' -trihidroxiestilbeno</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Calcined magnesia capsules, 500 mg, three times per day before meals with a total dose per day of 1500 mg</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Calcined magnesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients both sexes

          -  Age between 30 and 50 years

          -  Metabolic Syndrome according to the IDF criteria

          -  Waist circumference

          -  Man â‰¥90 cm

          -  Woman â‰¥80 cm

          -  And two of the following criteria:

          -  High density lipoprotein

          -  Man â‰¤40 mg/dL

          -  Woman â‰¤50 mg/dL

          -  Fasting glucose â‰¥100 mg/dL

          -  Triglycerides â‰¥150 mg/dL

          -  Blood pressure â‰¥130/85 mmHg

          -  Informed consent signed

        Exclusion Criteria:

          -  Women with confirmed or suspected pregnancy

          -  Women under lactation and/or puerperium

          -  Hypersensibility to resveratrol

          -  Physical impossibility for taking pills

          -  Known uncontrolled renal, hepatic, heart or thyroid diseased

          -  Previous treatment for the metabolic syndrome components

          -  Body Mass Index â‰¥39.9 kg/m2

          -  Fasting glucose â‰¥126 mg/dL

          -  Triglycerides â‰¥500 mg/dL

          -  Total cholesterol â‰¥240 mg/dL

          -  Low density lipoprotein (c-LDL) â‰¥190 mg/dL

          -  Blood Pressure â‰¥140/90 mmHg
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MANUEL GONZALEZ, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Guadalajara</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Intstituto de TerapeÃºtica Experimental y ClÃ­nica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>45037</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf</url>
    <description>INTERNATIONAL DIABETES FEDERATION CRITERIA FOR DIAGNOSIS OF METABOLIC SYNDROME</description>
  </link>
  <reference>
    <citation>Beaudeux JL, Nivet-Antoine V, Giral P. Resveratrol: a relevant pharmacological approach for the treatment of metabolic syndrome? Curr Opin Clin Nutr Metab Care. 2010 Nov;13(6):729-36. doi: 10.1097/MCO.0b013e32833ef291. Review.</citation>
    <PMID>20823772</PMID>
  </reference>
  <reference>
    <citation>Szkudelska K, Szkudelski T. Resveratrol, obesity and diabetes. Eur J Pharmacol. 2010 Jun 10;635(1-3):1-8. doi: 10.1016/j.ejphar.2010.02.054. Epub 2010 Mar 19. Review.</citation>
    <PMID>20303945</PMID>
  </reference>
  <reference>
    <citation>Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006 Jun;5(6):493-506. Epub 2006 May 26. Review.</citation>
    <PMID>16732220</PMID>
  </reference>
  <reference>
    <citation>Timmers S, Auwerx J, Schrauwen P. The journey of resveratrol from yeast to human. Aging (Albany NY). 2012 Mar;4(3):146-58. Review.</citation>
    <PMID>22436213</PMID>
  </reference>
  <reference>
    <citation>Kroon PA, Iyer A, Chunduri P, Chan V, Brown L. The cardiovascular nutrapharmacology of resveratrol: pharmacokinetics, molecular mechanisms and therapeutic potential. Curr Med Chem. 2010;17(23):2442-55. Review.</citation>
    <PMID>20491649</PMID>
  </reference>
  <reference>
    <citation>Baur JA. Resveratrol, sirtuins, and the promise of a DR mimetic. Mech Ageing Dev. 2010 Apr;131(4):261-9. doi: 10.1016/j.mad.2010.02.007. Epub 2010 Feb 26. Review.</citation>
    <PMID>20219519</PMID>
  </reference>
  <reference>
    <citation>Szkudelski T, Szkudelska K. Anti-diabetic effects of resveratrol. Ann N Y Acad Sci. 2011 Jan;1215:34-9. doi: 10.1111/j.1749-6632.2010.05844.x. Review.</citation>
    <PMID>21261639</PMID>
  </reference>
  <results_reference>
    <citation>Zhang J. Resveratrol inhibits insulin responses in a SirT1-independent pathway. Biochem J. 2006 Aug 1;397(3):519-27.</citation>
    <PMID>16626303</PMID>
  </results_reference>
  <results_reference>
    <citation>Rivera L, MorÃ³n R, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol. 2009 Mar 15;77(6):1053-63. doi: 10.1016/j.bcp.2008.11.027. Epub 2008 Dec 3.</citation>
    <PMID>19100718</PMID>
  </results_reference>
  <results_reference>
    <citation>Hung LM, Chen JK, Huang SS, Lee RS, Su MJ. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc Res. 2000 Aug 18;47(3):549-55.</citation>
    <PMID>10963727</PMID>
  </results_reference>
  <results_reference>
    <citation>Yu C, Shin YG, Chow A, Li Y, Kosmeder JW, Lee YS, Hirschelman WH, Pezzuto JM, Mehta RG, van Breemen RB. Human, rat, and mouse metabolism of resveratrol. Pharm Res. 2002 Dec;19(12):1907-14.</citation>
    <PMID>12523673</PMID>
  </results_reference>
  <results_reference>
    <citation>Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004 Dec;32(12):1377-82. Epub 2004 Aug 27.</citation>
    <PMID>15333514</PMID>
  </results_reference>
  <results_reference>
    <citation>Aumont V, Krisa S, Battaglia E, Netter P, Richard T, MÃ©rillon JM, Magdalou J, Sabolovic N. Regioselective and stereospecific glucuronidation of trans- and cis-resveratrol in human. Arch Biochem Biophys. 2001 Sep 15;393(2):281-9. PubMed PMID: 11556815.</citation>
    <PMID>11556815</PMID>
  </results_reference>
  <results_reference>
    <citation>Smoliga JM, Baur JA, Hausenblas HA. Resveratrol and health--a comprehensive review of human clinical trials. Mol Nutr Food Res. 2011 Aug;55(8):1129-41. doi: 10.1002/mnfr.201100143. Epub 2011 Jun 20. Review.</citation>
    <PMID>21688389</PMID>
  </results_reference>
  <results_reference>
    <citation>Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006 Nov 16;444(7117):337-42. Epub 2006 Nov 1.</citation>
    <PMID>17086191</PMID>
  </results_reference>
  <results_reference>
    <citation>Fischer-Posovszky P, Kukulus V, Tews D, Unterkircher T, Debatin KM, Fulda S, Wabitsch M. Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. Am J Clin Nutr. 2010 Jul;92(1):5-15. doi: 10.3945/ajcn.2009.28435. Epub 2010 May 12.</citation>
    <PMID>20463039</PMID>
  </results_reference>
  <results_reference>
    <citation>Baile CA, Yang JY, Rayalam S, Hartzell DL, Lai CY, Andersen C, Della-Fera MA. Effect of resveratrol on fat mobilization. Ann N Y Acad Sci. 2011 Jan;1215:40-7. doi: 10.1111/j.1749-6632.2010.05845.x. Review.</citation>
    <PMID>21261640</PMID>
  </results_reference>
  <results_reference>
    <citation>Alberdi G, RodrÃ­guez VM, Miranda J, Macarulla MT, Arias N, AndrÃ©s-Lacueva C, Portillo MP. Changes in white adipose tissue metabolism induced by resveratrol in rats. Nutr Metab (Lond). 2011 May 10;8(1):29. doi: 10.1186/1743-7075-8-29.</citation>
    <PMID>21569266</PMID>
  </results_reference>
  <results_reference>
    <citation>Bruckbauer A, Zemel MB, Thorpe T, Akula MR, Stuckey AC, Osborne D, Martin EB, Kennel S, Wall JS. Synergistic effects of leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes and mice. Nutr Metab (Lond). 2012 Aug 22;9(1):77. doi: 10.1186/1743-7075-9-77.</citation>
    <PMID>22913271</PMID>
  </results_reference>
  <results_reference>
    <citation>Ramadori G, Gautron L, Fujikawa T, Vianna CR, Elmquist JK, Coppari R. Central administration of resveratrol improves diet-induced diabetes. Endocrinology. 2009 Dec;150(12):5326-33. doi: 10.1210/en.2009-0528. Epub 2009 Oct 9.</citation>
    <PMID>19819963</PMID>
  </results_reference>
  <results_reference>
    <citation>Szkudelski T. Resveratrol-induced inhibition of insulin secretion from rat pancreatic islets: evidence for pivotal role of metabolic disturbances. Am J Physiol Endocrinol Metab. 2007 Oct;293(4):E901-7. Epub 2007 Jun 19.</citation>
    <PMID>17578889</PMID>
  </results_reference>
  <results_reference>
    <citation>Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006 Dec 15;127(6):1109-22. Epub 2006 Nov 16.</citation>
    <PMID>17112576</PMID>
  </results_reference>
  <results_reference>
    <citation>Penumathsa SV, Thirunavukkarasu M, Zhan L, Maulik G, Menon VP, Bagchi D, Maulik N. Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium. J Cell Mol Med. 2008 Dec;12(6A):2350-61. doi: 10.1111/j.1582-4934.2008.00251.x. Erratum in: J Cell Mol Med. 2010 Oct;14(10):2539.</citation>
    <PMID>18266981</PMID>
  </results_reference>
  <results_reference>
    <citation>Dao TM, Waget A, Klopp P, Serino M, Vachoux C, Pechere L, Drucker DJ, Champion S, BarthÃ©lemy S, Barra Y, Burcelin R, SÃ©rÃ©e E. Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control. PLoS One. 2011;6(6):e20700. doi: 10.1371/journal.pone.0020700. Epub 2011 Jun 6.</citation>
    <PMID>21673955</PMID>
  </results_reference>
  <results_reference>
    <citation>BrasnyÃ³ P, MolnÃ¡r GA, MohÃ¡s M, MarkÃ³ L, Laczy B, Cseh J, MikolÃ¡s E, SzijÃ¡rtÃ³ IA, MÃ©rei A, Halmai R, MÃ©szÃ¡ros LG, SÃ¼megi B, Wittmann I. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 2011 Aug;106(3):383-9. doi: 10.1017/S0007114511000316. Epub 2011 Mar 9.</citation>
    <PMID>21385509</PMID>
  </results_reference>
  <results_reference>
    <citation>Crandall JP, Oram V, Trandafirescu G, Reid M, Kishore P, Hawkins M, Cohen HW, Barzilai N. Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci. 2012 Dec;67(12):1307-12. doi: 10.1093/gerona/glr235. Epub 2012 Jan 4.</citation>
    <PMID>22219517</PMID>
  </results_reference>
  <results_reference>
    <citation>Szkudelski T. Resveratrol inhibits insulin secretion from rat pancreatic islets. Eur J Pharmacol. 2006 Dec 15;552(1-3):176-81. Epub 2006 Sep 27.</citation>
    <PMID>17069794</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 11, 2014</lastchanged_date>
  <firstreceived_date>April 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Manuel GonzÃ¡lez Ortiz</investigator_full_name>
    <investigator_title>Senior Researcher</investigator_title>
  </responsible_party>
  <keyword>metabolic syndrome</keyword>
  <keyword>central obesity</keyword>
  <keyword>resveratrol</keyword>
  <keyword>insulin secretion</keyword>
  <keyword>insulin sensitivity</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Magnesium Oxide</mesh_term>
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
